We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

68 hedge funds and large institutions have $72.3M invested in CASI Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 14 increasing their positions, 23 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.46% less ownership

Funds ownership: 3.8% → 3.34% (-0.46%)

20% less funds holding

Funds holding: 85 → 68 (-17)

39% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 23

43% less capital invested

Capital invested by funds: $127M → $72.3M (-$55.1M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

50% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 34

Holders
68
Holders Change
-17
Holders Change %
-20%
% of All Funds
1.18%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
17
Increased
14
Reduced
23
Closed
34
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$2.17M
2
Millennium Management
Millennium Management
New York
+$1.73M
3
E
Ergoteles
New York
+$505K
4
Marshall Wace
Marshall Wace
United Kingdom
+$376K
5
TEE
Tibra Equities Europe
United Kingdom
+$364K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$4.75M
2
TLP
Tri Locum Partners
New York
-$3.6M
3
BCM
Bridgeway Capital Management
Texas
-$1.51M
4
State Street
State Street
Massachusetts
-$1.42M
5
Northern Trust
Northern Trust
Illinois
-$971K

CASI Hedge Fund Activity: Q2 2021 in Review

68 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q2 2021, worth a combined $72.3M — down 43% from $127M a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of CASI and 17 opened new positions — a net loss of 17 holders — while 23 trimmed existing stakes and 14 added.

The largest buyer was Renaissance Technologies, adding an estimated $2.17M. The largest seller was BlackRock, cutting an estimated $4.75M.

  • 68 institutional investors held CASI Pharmaceuticals (CASI) as of Q2 2021, down from 85 in Q1 2021.
  • Funds reported $72.3M of CASI Pharmaceuticals stock for Q2 2021, down 43% quarter-over-quarter.
  • 17 funds opened new CASI Pharmaceuticals positions in Q2 2021 and 34 closed out, a net change of -17 holders.
  • The largest CASI Pharmaceuticals buyer in Q2 2021 was Renaissance Technologies, an estimated $2.17M added.
  • The largest CASI Pharmaceuticals seller in Q2 2021 was BlackRock, an estimated $4.75M sold.

Based on aggregated 13F filings for Q2 2021.